Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Perceptive Advisors
AddedFeb 13, 2024
UpdatedJul 16, 2026
Perceptive Advisors

Perceptive Advisors

Operating

Perceptive: A hedge fund sponsor investing in promising healthcare technologies to advance life sciences.

Location
New York City, NY, US
Founded
1999
Firm
Compare
Portfolio
Employees
Website

Investments

Astria Therapeutics
Astria Therapeutics
Public

Total Raised

$656.4M

Rounds

18

Post Ipo Equity$125MJanuary 2024
Apyx Medical
Apyx Medical
Public

Total Raised

$160.5M

Rounds

7

Post Ipo Debt$37.5MNovember 2023
enVVeno Medical
enVVeno Medical
Public

Total Raised

$28M

Rounds

2

Post Ipo Equity$28MOctober 2023
Soleno Therapeutics
Soleno Therapeutics
Public

Total Raised

$160.5M

Rounds

4

Post Ipo Equity$129MSeptember 2023
Avalyn Pharma
Avalyn Pharma

Total Raised

$272.5M

Rounds

3

Series C$175MSeptember 2023
Beta Bionics
Beta Bionics

Total Raised

$293.5M

Rounds

8

Series D$100MAugust 2023
Rapport Therapeutics
Rapport Therapeutics

Total Raised

$250M

Rounds

2

Series B$150MAugust 2023
Forte Biosciences
Forte Biosciences
Public

Total Raised

$70.8M

Rounds

4

Post Ipo Debt$25MAugust 2023
AsclepiX Therapeutics
AsclepiX Therapeutics

Total Raised

$50M

Rounds

3

Series A$10MJuly 2023
A-Alpha Bio
A-Alpha Bio

Total Raised

$49.6M

Rounds

8

Series A$22.4MJuly 2023
Lyra Therapeutics
Lyra Therapeutics
Public

Total Raised

$264.1M

Rounds

11

Post Ipo Equity$50MMay 2023
Post Ipo Equity$100.5MApril 2022
OnKure Therapeutics
OnKure Therapeutics
Public

Total Raised

$121.5M

Rounds

8

Series C$54MMay 2023
Torl Biotherapeutics
Torl Biotherapeutics

Total Raised

$158M

Rounds

1

Series B$158MApril 2023
Kindbody
Kindbody

Total Raised

$306.3M

Rounds

10

Debt Financing$100MMarch 2023
Biodesix
Biodesix
Public

Total Raised

$390.3M

Rounds

22

Post Ipo Debt$50MNovember 2022
Solid Biosciences
Solid Biosciences
Public

Total Raised

$441.3M

Rounds

8

Post Ipo Equity$75MSeptember 2022
SpringWorks Therapeutics
SpringWorks Therapeutics
Public

Total Raised

$1B

Rounds

6

Post Ipo Equity$225MSeptember 2022
MeiraGTx Holdings
MeiraGTx Holdings
Public

Total Raised

$112M

Rounds

5

Post Ipo Debt$75MAugust 2022
Cerebral Therapeutics
Cerebral Therapeutics

Total Raised

$85.8M

Rounds

4

Series C$40MJune 2022
Surf Bio
Surf Bio

Total Raised

$16M

Rounds

1

Seed$16MApril 2022
VivoSense
VivoSense

Total Raised

$27M

Rounds

3

Series A$25MMarch 2022
Neuron23
Neuron23

Total Raised

$213.5M

Rounds

4

Series C$100MMarch 2022
Dnanexus
Dnanexus

Total Raised

$472.6M

Rounds

9

Series H$200MMarch 2022
Omada Health
Omada Health

Total Raised

$528.5M

Rounds

11

Series E$192MFebruary 2022